Loading MDT detail
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide.
Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Chart data unavailable

CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced a digital integration between the GE HealthCare bkActiv™ intraoperative ultrasound (iUS) system and the Medtronic Stealth AXiS™ surgical navigation system, which is now commercially available to provide real-time advanced imaging during cranial procedures to complement surgical planning and navigation workflows. This integration builds on an existing strategic alliance between the companies to accelerate next-generation technology innovati.

In the latest trading session, Medtronic (MDT) closed at $88.65, marking a +2.58% move from the previous day.

From energy to healthcare, this trio of reliable dividend payers are worth a deep dive today.

Savvy Advisors Inc. grew its stake in shares of Medtronic PLC (NYSE: MDT) by 85.4% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,777 shares of the medical technology company's stock after acquiring an additional 13,716

Medtronic (NYSE: MDT - Get Free Report) and Omeros (NASDAQ: OMER - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends. Volatility and Risk Medtronic has a beta of 0.75, suggesting

Medtronic (NYSE: MDT - Get Free Report) and MacroGenics (NASDAQ: MGNX - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk and analyst recommendations. Profitability This table compares Medtronic and MacroGenics' net margins, return

Stratos Wealth Partners LTD. cut its stake in shares of Medtronic PLC (NYSE: MDT) by 9.1% during the undefined quarter, according to its most recent filing with the SEC. The institutional investor owned 74,371 shares of the medical technology company's stock after selling 7,442 shares during the period. Stratos Wealth Partners LTD.'s holdings

Cardiovascular disease may be one of medicine’s oldest battlegrounds, but some of its most important technologies are still evolving — and not always as...

Tilray Inc (NASDAQ:TLRY) earned a repeat ‘Buy’ rating from Jefferies analysts after what it described as a solid third quarter earnings report, pointing to...

Foundayo launches on April 6 at the same price as Novo's pill, threatening to reshape the $50 billion obesity drug market before Novo's first-quarter...

The forex market now turns over $9.6 trillion every single day. That figure, confirmed by the Bank for International Settlements in its 2025 Triennial...

Medtronic wins FDA's approval for Stealth AXiS in cranial & ENT, expanding its AI-driven surgical platform after spine clearance and boosting growth prospects.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from the ALERT (Addressing undertreatment and heaLth Equity in aortic stenosis and mitral regurgitation using an integrated ehR plaTform) trial, which were recently presented at the American College of Cardiology's 75th Annual Scientific Session & Expo. The study, conducted in collaboration with Medtronic, found that automated electr.

Medtronic (MDT) concluded the recent trading session at $85.74, signifying a -1.61% move from its prior day's close.

Medtronic plc is a stable medical device company currently trading below analyst price targets and undervalued, presenting a potential short-term value opportunity. GLP-1 drugs may not materially threaten MDT; patient discontinuation rates and new surgical eligibility could offset potential cardiovascular equipment demand declines. Revenue and net margin growth are steady, and with product innovation and new market introductions, it is believed to grow at triple the historical rate.